<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1387">
  <stage>Registered</stage>
  <submitdate>27/11/2006</submitdate>
  <approvaldate>27/11/2006</approvaldate>
  <nctid>NCT00405119</nctid>
  <trial_identification>
    <studytitle>A Study To Investigate The Effectiveness Of AH234844 (Lavoltidine) Compared With NEXIUM And Ranitidine.</studytitle>
    <scientifictitle>A Randomized, Double-blind, Four Period Cross-over Comparison of the Effect of Two Doses Lavoltidine, Esomeprazole, and Placebo on 24 Hour Gastric pH and Frequency of Heartburn in Symptomatic GERD Subjects Without Esophageal Erosions</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>LAV104616</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gastroesophageal Reflux Disease</healthcondition>
    <healthcondition>Reflux, Gastroesophageal</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AH23844 (lavoltidine)
Treatment: drugs - NEXIUM (esomeprazole)
Treatment: drugs - ZANTAC (ranitidine)

Treatment: drugs: AH23844 (lavoltidine)


Treatment: drugs: NEXIUM (esomeprazole)


Treatment: drugs: ZANTAC (ranitidine)


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>pH over 24hours</outcome>
      <timepoint>over 24hours</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>%24 hours pH&gt;4 Median gastric pH Adverse events</outcome>
      <timepoint>over 24 hours</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Subject must have a Body Mass Index (BMI) from 19-30 kg/m2

          -  Subject does not present with abnormal clinical lab findings

          -  Subject is able to tolerate a nasogastric pH electrode.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Subject is Helicobacter-positive on a C13 urea breath test

          -  Subject has a baseline median 24-hour gastric pH&gt;3

          -  For Part B of the study, subjects are CYP 2C19 poor metabolizers.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>92</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD</recruitmentstate>
    <hospital>GSK Investigational Site - Randwick</hospital>
    <hospital>GSK Investigational Site - Herston</hospital>
    <postcode>2031 - Randwick</postcode>
    <postcode>4006 - Herston</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Current treatment for gastroesophageal reflux disease (GERD) confirms an unmet need in
      patients, based on slow onset of action and an inability to provide 24-hour gastric-acid
      suppression. Clinical data on AH234844 demonstrates a rapid onset of action, high potency,
      and prolonged duration of effect. The present study endeavors, in part, to compare
      lavoltidine to two GERD drugs, NEXIUM and ranitidine.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00405119</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>